Melatonín

Literatúra

  1. Hattori A, et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int. (1995)
  2. Peuhkuri K, Sihvola N, Korpela R. Dietary factors and fluctuating levels of melatonin. Food Nutr Res. (2012)
  3. Tan DX, et al. Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science. J Exp Bot. (2012)
  4. Iriti M, Varoni EM, Vitalini S. Melatonin in traditional Mediterranean diets. J Pineal Res. (2010)
  5. Determination of the melatonin content of different varieties of tomatoes (Lycopersicon esculentum) and strawberries (Fragariaananassa).
  6. Reiter RJ, Manchester LC, Tan DX. Melatonin in walnuts: influence on levels of melatonin and total antioxidant capacity of blood. Nutrition. (2005)
  7. Melatonin is a phytochemical in olive oil.
  8. Diurnal pattern of melatonin in blood and milk of dairy Cows.
  9. Hormones in bovine milk and milk products: A survey.
  10. Valtonen M, et al. Effect of melatonin-rich night-time milk on sleep and activity in elderly institutionalized subjects. Nord J Psychiatry. (2005)
  11. Melatonin: A new bioactive compound in wine.
  12. Maldonado MD, Moreno H, Calvo JR. Melatonin present in beer contributes to increase the levels of melatonin and antioxidant capacity of the human serum. Clin Nutr. (2009)
  13. Burkhardt S, et al. Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (Prunus cerasus). J Agric Food Chem. (2001)
  14. Chen G, et al. Melatonin in Chinese medicinal herbs. Life Sci. (2003)
  15. Sanchez-Hidalgo M, et al. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol. (2007)
  16. Bernard M, et al. Melatonin synthesis pathway: circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. Reprod Nutr Dev. (1999)
  17. Localization, Physiological Significance and Possible Clinical Implication of Gastrointestinal Melatonin.
  18. Bubenik GA, Konturek SJ. Melatonin and aging: prospects for human treatment. J Physiol Pharmacol. (2011)
  19. Kollmann MT, et al. Effects of tryptophan supplementation on plasma tryptophan and related hormone levels in heifers and dairy cows. Domest Anim Endocrinol. (2008)
  20. Herrero MJ, et al. Response of plasma and gastrointestinal melatonin, plasma cortisol and activity rhythms of European sea bass (Dicentrarchus labrax) to dietary supplementation with tryptophan and melatonin. J Comp Physiol B. (2007)
  21. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci. (2008)
  22. Klein DC. Arylalkylamine N-acetyltransferase: „the Timezyme“. J Biol Chem. (2007)
  23. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. (1994)
  24. Matsumoto M, et al. The amplitude of endogenous melatonin production is not affected by melatonin treatment in humans. J Pineal Res. (1997)
  25. Wright J, et al. The effects of exogenous melatonin on endocrine function in man. Clin Endocrinol (Oxf). (1986)
  26. Arendt J, et al. Some effects of melatonin and the control of its secretion in humans. Ciba Found Symp. (1985)
  27. Hack LM, et al. The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. J Biol Rhythms. (2003)
  28. Annual rhythm of serum melatonin in man.
  29. Dijk DJ, Duffy JF. Circadian regulation of human sleep and age-related changes in its timing, consolidation and EEG characteristics. Ann Med. (1999)
  30. Pang SF, Tang F, Tang PL. Negative correlation of age and the levels of pineal melatonin, pineal N-acetylserotonin, and serum melatonin in male rats. J Exp Zool. (1984)
  31. Waldhauser F, Kovács J, Reiter E. Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Exp Gerontol. (1998)
  32. Wetterberg L, et al. Normative melatonin excretion: a multinational study. Psychoneuroendocrinology. (1999)
  33. Benot S, et al. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res. (1999)
  34. Pandi-Perumal SR, et al. Melatonin and sleep in aging population. Exp Gerontol. (2005)
  35. Reiter RJ. The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Exp Gerontol. (1995)
  36. Nagata C, et al. Association of vegetable intake with urinary 6-sulfatoxymelatonin level. Cancer Epidemiol Biomarkers Prev. (2005)
  37. Michalsen A, et al. Effects of short-term modified fasting on sleep patterns and daytime vigilance in non-obese subjects: results of a pilot study. Ann Nutr Metab. (2003)
  38. Röjdmark S, Rössner S, Wetterberg L. Effect of short-term fasting on nocturnal melatonin secretion in obesity. Metabolism. (1992)
  39. Röjdmark S, Wetterberg L. Short-term fasting inhibits the nocturnal melatonin secretion in healthy man. Clin Endocrinol (Oxf). (1989)
  40. Stokkan KA, et al. Endocrine and metabolic effects of life-long food restriction in rats. Acta Endocrinol (Copenh). (1991)
  41. Beck-Friis J, et al. Melatonin in relation to body measures, sex, age, season and the use of drugs in patients with major affective disorders and healthy subjects. Psychoneuroendocrinology. (1984)
  42. Tarquini B, et al. Daytime circulating melatonin levels in smokers. Tumori. (1994)
  43. Ozguner F, Koyu A, Cesur G. Active smoking causes oxidative stress and decreases blood melatonin levels. Toxicol Ind Health. (2005)
  44. Ursing C, et al. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol. (2005)
  45. Schrenk D, et al. A distribution study of CYP1A2 phenotypes among smokers and nonsmokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol. (1998)
  46. The Pineal Peptide Preparation, Epithalamin, Slows Aging in Drosophila melanogaster, Mice, and Rats.
  47. Anisimov VN, et al. Effect of melatonin and pineal peptide preparation epithalamin on life span and free radical oxidation in Drosophila melanogaster. Mech Ageing Dev. (1997)
  48. Korkushko OV, et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. (2011)
  49. Mixon MB, et al. Tertiary and quaternary structural changes in Gi alpha 1 induced by GTP hydrolysis. Science. (1995)
  50. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. (2005)
  51. Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci. (1996)
  52. Roca AL, et al. Structure, characterization, and expression of the gene encoding the mouse Mel1a melatonin receptor. Endocrinology. (1996)
  53. Dubocovich ML, et al. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. (1997)
  54. Slaugenhaupt SA, et al. Mapping of the gene for the Mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics. (1995)
  55. Dubocovich ML, et al. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. (2003)
  56. Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE. (2001)
  57. Popova JS, Dubocovich ML. Melatonin receptor-mediated stimulation of phosphoinositide breakdown in chick brain slices. J Neurochem. (1995)
  58. Nosjean O, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. (2000)
  59. Nosjean O, et al. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol. (2001)
  60. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores.
  61. Becker-André M, et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem. (1994)
  62. Yasuo S, et al. Melatonin transmits photoperiodic signals through the MT1 melatonin receptor. J Neurosci. (2009)
  63. Ishii H, et al. Gene structures, biochemical characterization and distribution of rat melatonin receptors. J Physiol Sci. (2009)
  64. Mühlbauer E, Peschke E. Evidence for the expression of both the MT1- and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and beta-cell. J Pineal Res. (2007)
  65. Kazantzis M, et al. PAZ6 cells constitute a representative model for human brown pre-adipocytes. Front Endocrinol (Lausanne). (2012)
  66. Reppert SM, et al. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett. (1996)
  67. Bechtold DA, et al. A role for the melatonin-related receptor GPR50 in leptin signaling, adaptive thermogenesis, and torpor. Curr Biol. (2012)
  68. Sidibe A, et al. Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. J Pineal Res. (2010)
  69. Ivanova EA, et al. Altered metabolism in the melatonin-related receptor (GPR50) knockout mouse. Am J Physiol Endocrinol Metab. (2008)
  70. Swoap SJ. Thermoregulation: an orphan receptor finds its way in the cold. Curr Biol. (2012)
  71. Jockers R, et al. Melatonin receptors, heterodimerization, signal transduction and binding sites: what’s new. Br J Pharmacol. (2008)
  72. Levoye A, et al. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. (2006)
  73. Mundey K, et al. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep. (2005)
  74. Melatonin Treatment for Age-Related Insomnia.
  75. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period.
  76. Sack RL, et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. (2000)
  77. Dawson D, Gibbon S, Singh P. The hypothermic effect of melatonin on core body temperature: is more better. J Pineal Res. (1996)
  78. Meeking DR, et al. Exercise-induced GH secretion is enhanced by the oral ingestion of melatonin in healthy adult male subjects. Eur J Endocrinol. (1999)
  79. Mero AA, et al. Effects of resistance exercise session after oral ingestion of melatonin on physiological and performance responses of adult men. Eur J Appl Physiol. (2006)
  80. Cagnacci A, Soldani R, Yen SS. Melatonin enhances cortisol levels in aged women: reversible by estrogens. J Pineal Res. (1997)
  81. Cagnacci A, Elliott JA, Yen SS. Amplification of pulsatile LH secretion by exogenous melatonin in women. J Clin Endocrinol Metab. (1991)
  82. Waldhauser F, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology. (1984)
  83. Markantonis SL, et al. Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers. J Clin Pharmacol. (2008)
  84. Wetterberg L, et al. A simplified radioimmunoassay for melatonin and its application to biological fluids. Preliminary observations on the half-life of plasma melatonin in man. Clin Chim Acta. (1978)
  85. Bechgaard E, Lindhardt K, Martinsen L. Intranasal absorption of melatonin in vivo bioavailability study. Int J Pharm. (1999)
  86. Ma X, et al. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. (2005)
  87. Facciolá G, et al. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol. (2001)
  88. Skene DJ, et al. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J Pineal Res. (2001)
  89. Grözinger M, et al. Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile. Arch Gen Psychiatry. (2000)
  90. Härtter S, et al. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther. (2000)
  91. Rimmele U, et al. Melatonin improves memory acquisition under stress independent of stress hormone release. Psychopharmacology (Berl). (2009)
  92. Arangino S, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol. (1999)
  93. Nishiyama K, et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J. (2001)
  94. Cagnacci A, et al. Influences of melatonin administration on the circulation of women. Am J Physiol. (1998)
  95. Zisapel N, Laudon M. Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: inhibition by melatonin. Biochem Biophys Res Commun. (1982)
  96. Zisapel N, Egozi Y, Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res. (1982)
  97. Zisapel N, Laudon M. Inhibition by melatonin of dopamine release from rat hypothalamus: regulation of calcium entry. Brain Res. (1983)
  98. Escames G, et al. Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum. J Neuroendocrinol. (2001)
  99. Shieh KR, Chu YS, Pan JT. Circadian change of dopaminergic neuron activity: effects of constant light and melatonin. Neuroreport. (1997)
  100. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol. (2001)
  101. Exposito I, Mora F, Oaknin S. Dopamine-glutamic acid interaction in the anterior hypothalamus: modulatory effect of melatonin. Neuroreport. (1995)
  102. Exposito I, et al. The modulatory effect of melatonin on the dopamine-glutamate interaction in the anterior hypothalamus during ageing. Neuroreport. (1995)
  103. Jin X, et al. Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol. (2003)
  104. von Gall C, et al. Melatonin limits transcriptional impact of phosphoCREB in the mouse SCN via the Mel1a receptor. Neuroreport. (2000)
  105. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock.
  106. Kunz D, et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. (2004)
  107. Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. (2007)
  108. Dubocovich ML, et al. Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J Pineal Res. (2005)
  109. McArthur AJ, Hunt AE, Gillette MU. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: activation of protein kinase C at dusk and dawn. Endocrinology. (1997)
  110. Shibata S, Cassone VM, Moore RY. Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci Lett. (1989)
  111. Liu C, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. (1997)
  112. Forsling ML, Williams AJ. The effect of exogenous melatonin on stimulated neurohypophysial hormone release in man. Clin Endocrinol (Oxf). (2002)
  113. Forsling ML, Wheeler MJ, Williams AJ. The effect of melatonin administration on pituitary hormone secretion in man. Clin Endocrinol (Oxf). (1999)
  114. Kostoglou-Athanassiou I, et al. Melatonin administration and pituitary hormone secretion. Clin Endocrinol (Oxf). (1998)
  115. Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin. (2006)
  116. Koh PO. Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neurosci Lett. (2008)
  117. Kongsuphol P, et al. Melatonin attenuates methamphetamine-induced deactivation of the mammalian target of rapamycin signaling to induce autophagy in SK-N-SH cells. J Pineal Res. (2009)
  118. Kimball SR, Abbas A, Jefferson LS. Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of Ras. J Pineal Res. (2008)
  119. Kwon KJ, et al. Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. J Clin Neurol. (2010)
  120. Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. Altern Med Rev. (2001)
  121. Alstadhaug K, Salvesen R, Bekkelund S. 24-hour distribution of migraine attacks. Headache. (2008)
  122. Alstadhaug K, Salvesen R, Bekkelund S. Insomnia and circadian variation of attacks in episodic migraine. Headache. (2007)
  123. Alstadhaug KB, et al. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. (2010)
  124. Peres MF. Melatonin for migraine prevention. Curr Pain Headache Rep. (2011)
  125. Seabra ML, et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. (2000)
  126. Ferini-Strambi L, et al. Effect of melatonin on sleep microstructure: preliminary results in healthy subjects. Sleep. (1993)
  127. James SP, et al. The effect of melatonin on normal sleep. Neuropsychopharmacology. (1987)
  128. Cramer H, et al. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol. (1974)
  129. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl). (1990)
  130. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance.
  131. Nave R, Peled R, Lavie P. Melatonin improves evening napping. Eur J Pharmacol. (1995)
  132. Reid K, Van den Heuvel C, Dawson D. Day-time melatonin administration: effects on core temperature and sleep onset latency. J Sleep Res. (1996)
  133. Zhdanova IV, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. (1995)
  134. Zhdanova IV, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep. (1996)
  135. Pinto LR Jr, Seabra Mde L, Tufik S. Different criteria of sleep latency and the effect of melatonin on sleep consolidation. Sleep. (2004)
  136. Wade AG, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. (2010)
  137. Wade AG, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. (2011)
  138. Lemoine P, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. (2007)
  139. Luthringer R, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. (2009)
  140. van Geijlswijk IM, et al. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology (Berl). (2011)
  141. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. (1970)
  142. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. (1969)
  143. Hurtuk A, et al. Melatonin: can it stop the ringing. Ann Otol Rhinol Laryngol. (2011)
  144. Requintina PJ, et al. Synergistic sedative effect of selective MAO-A, but not MAO-B, inhibitors and melatonin in frogs. J Neural Transm Suppl. (1994)
  145. Rajaratnam SM, Arendt J. Health in a 24-h society. Lancet. (2001)
  146. Kiessling S, Eichele G, Oster H. Adrenal glucocorticoids have a key role in circadian resynchronization in a mouse model of jet lag. J Clin Invest. (2010)
  147. Efficacy of Melatonin Treatment in Jet Lag, Shift Work, and Blindness.
  148. Pfeffer M, et al. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors. Chronobiol Int. (2012)
  149. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. (2002)
  150. Spitzer RL, et al. Jet lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. Am J Psychiatry. (1999)
  151. Suhner A, et al. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviat Space Environ Med. (2001)
  152. Beaumont M, et al. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J Appl Physiol. (2004)
  153. Petrie K, et al. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry. (1993)
  154. Claustrat B, et al. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry. (1992)
  155. Piérard C, et al. Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slow-release caffeine and melatonin. Eur J Appl Physiol. (2001)
  156. Edwards BJ, et al. Use of melatonin in recovery from jet-lag following an eastward flight across 10 time-zones. Ergonomics. (2000)
  157. Sharkey KM, Eastman CI. Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study. Am J Physiol Regul Integr Comp Physiol. (2002)
  158. Samel A, et al. Influence of melatonin treatment on human circadian rhythmicity before and after a simulated 9-hr time shift. J Biol Rhythms. (1991)
  159. Paul MA, et al. Phase advance with separate and combined melatonin and light treatment. Psychopharmacology (Berl). (2011)
  160. Preflight Adjustment to Eastward Travel: 3 Days of Advancing Sleep with and without Morning Bright Light.
  161. Revell VL, et al. Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. J Clin Endocrinol Metab. (2006)
  162. Wirz-Justice A, et al. Evening melatonin and bright light administration induce additive phase shifts in dim light melatonin onset. J Pineal Res. (2004)
  163. Kitaoka K, et al. Fermented ginseng improves the first-night effect in humans. Sleep. (2009)
  164. http://humrep.oxfordjournals.org/content/15/1/60.full.pdf.
  165. Shamir E, et al. First-night effect of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol. (2000)
  166. Shamir E, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. (2000)
  167. Lewy AJ, et al. Antidepressant and circadian phase-shifting effects of light. Science. (1987)
  168. Teicher MH, et al. Circadian rest-activity disturbances in seasonal affective disorder. Arch Gen Psychiatry. (1997)
  169. Lewy AJ, et al. The circadian basis of winter depression. Proc Natl Acad Sci U S A. (2006)
  170. Lewy AJ, et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int. (1998)
  171. Biology of Depression: From Novel Insights to Therapeutic Strategies.
  172. Rondanelli M, et al. Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. Nutr Neurosci. (2012)
  173. Genade S, et al. Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions. J Pineal Res. (2008)
  174. Cook JS, Sauder CL, Ray CA. Melatonin differentially affects vascular blood flow in humans. Am J Physiol Heart Circ Physiol. (2011)
  175. Koziróg M, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. (2011)
  176. Maldonado MD, et al. Melatonin administered immediately before an intense exercise reverses oxidative stress, improves immunological defenses and lipid metabolism in football players. Physiol Behav. (2012)
  177. Celinski K, et al. Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res. (2011)
  178. Gonciarz M, et al. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. J Pineal Res. (2012)
  179. Ríos-Lugo MJ, et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. J Pineal Res. (2010)
  180. Song YM, Chen MD. Effects of melatonin administration on plasma leptin concentration and adipose tissue leptin secretion in mice. Acta Biol Hung. (2009)
  181. Baltaci AK, Mogulkoc R. Pinealectomy and melatonin administration in rats: their effects on plasma leptin levels and relationship with zinc. Acta Biol Hung. (2007)
  182. Alonso-Vale MI, et al. Melatonin enhances leptin expression by rat adipocytes in the presence of insulin. Am J Physiol Endocrinol Metab. (2005)
  183. Alonso-Vale MI, et al. Intermittent and rhythmic exposure to melatonin in primary cultured adipocytes enhances the insulin and dexamethasone effects on leptin expression. J Pineal Res. (2006)
  184. Borges-Silva CN, et al. Reduced lipolysis and increased lipogenesis in adipose tissue from pinealectomized rats adapted to training. J Pineal Res. (2005)
  185. Zhang L, et al. Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression. J Pineal Res. (2010)
  186. Alonso-Vale MI, et al. Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity. J Pineal Res. (2009)
  187. Zwirska-Korczala K, et al. Influence of melatonin on cell proliferation, antioxidative enzyme activities and lipid peroxidation in 3T3-L1 preadipocytes–an in vitro study. J Physiol Pharmacol. (2005)
  188. Zalatan F, Krause JA, Blask DE. Inhibition of isoproterenol-induced lipolysis in rat inguinal adipocytes in vitro by physiological melatonin via a receptor-mediated mechanism. Endocrinology. (2001)
  189. Wolden-Hanson T, et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology. (2000)
  190. Stratos I, et al. Melatonin restores muscle regeneration and enhances muscle function after crush injury in rats. J Pineal Res. (2012)
  191. Wang WZ, et al. Melatonin attenuates I/R-induced mitochondrial dysfunction in skeletal muscle. J Surg Res. (2011)
  192. Hibaoui Y, Roulet E, Ruegg UT. Melatonin prevents oxidative stress-mediated mitochondrial permeability transition and death in skeletal muscle cells. J Pineal Res. (2009)
  193. Atkinson G, et al. Are there hangover-effects on physical performance when melatonin is ingested by athletes before nocturnal sleep. Int J Sports Med. (2001)
  194. Atkinson G, et al. Effects of daytime ingestion of melatonin on short-term athletic performance. Ergonomics. (2005)
  195. Schernhammer ES, et al. A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes Control. (2012)
  196. Cos S, et al. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. (2005)
  197. González A, et al. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep. (2007)
  198. Girgert R, et al. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res. (2009)
  199. Knower KC, et al. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat. (2012)
  200. Frungieri MB, et al. Direct effect of melatonin on Syrian hamster testes: melatonin subtype 1a receptors, inhibition of androgen production, and interaction with the local corticotropin-releasing hormone system. Endocrinology. (2005)
  201. Dufau ML, Tinajero JC, Fabbri A. Corticotropin-releasing factor: an antireproductive hormone of the testis. FASEB J. (1993)
  202. Rossi SP, et al. New insights into melatonin/CRH signaling in hamster Leydig cells. Gen Comp Endocrinol. (2012)
  203. Frungieri MB, Gonzalez-Calvar SI, Calandra RS. Polyamine levels in testes and seminal vesicles from adult golden hamsters during gonadal regression-recrudescence. J Androl. (1996)
  204. Valcavi R, et al. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone. Clin Endocrinol (Oxf). (1993)
  205. Smythe GA, Lazarus L. Suppression of human growth hormone secretion by melatonin and cyproheptadine. J Clin Invest. (1974)
  206. Nassar E, et al. Effects of a single dose of N-Acetyl-5-methoxytryptamine (Melatonin) and resistance exercise on the growth hormone/IGF-1 axis in young males and females. J Int Soc Sports Nutr. (2007)
  207. Melatonin As a Free Radical Scavenger: Implications for Aging and Age-Related Diseases.
  208. Allegra M, et al. The chemistry of melatonin’s interaction with reactive species. J Pineal Res. (2003)
  209. Reiter RJ, et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys. (2001)
  210. Poeggeler B, et al. Melatonin–a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci. (1994)
  211. Reaction of Melatonin and Related Indoles With Hydroxyl Radicals: EPR and Spin Trapping Investigations.
  212. Noda Y, et al. Melatonin and its precursors scavenge nitric oxide. J Pineal Res. (1999)
  213. Zhang H, Squadrito GL, Pryor WA. The reaction of melatonin with peroxynitrite: formation of melatonin radical cation and absence of stable nitrated products. Biochem Biophys Res Commun. (1998)
  214. López-Burillo S, et al. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. J Pineal Res. (2003)
  215. Kandil TS, et al. The potential therapeutic effect of melatonin in Gastroesophageal Reflux Disease. BMC Gastroenterol. (2010)
  216. Celinski K, et al. Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans. J Physiol Pharmacol. (2011)
  217. Melatonin orl-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole.
  218. Konturek PC, et al. Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. J Pineal Res. (2010)
  219. Osborne NN, Chidlow G. The presence of functional melatonin receptors in the iris-ciliary processes of the rabbit eye. Exp Eye Res. (1994)
  220. Alarma-Estrany P, et al. Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits. J Pineal Res. (2008)
  221. Wiechmann AF, Wirsig-Wiechmann CR. Melatonin receptor mRNA and protein expression in Xenopus laevis nonpigmented ciliary epithelial cells. Exp Eye Res. (2001)
  222. Samples JR, Krause G, Lewy AJ. Effect of melatonin on intraocular pressure. Curr Eye Res. (1988)
  223. Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg. (2009)
  224. Crooke A, et al. Regulation of ocular adrenoceptor genes expression by 5-MCA-NAT: implications for glaucoma treatment. Pharmacogenet Genomics. (2011)
  225. Crooke A, et al. Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT. J Pineal Res. (2012)
  226. Chiquet C, et al. Melatonin concentrations in aqueous humor of glaucoma patients. Am J Ophthalmol. (2006)
  227. Yu HS, et al. Diurnal rhythms of immunoreactive melatonin in the aqueous humor and serum of male pigmented rabbits. Neurosci Lett. (1990)
  228. Mediero A, Alarma-Estrany P, Pintor J. New treatments for ocular hypertension. Auton Neurosci. (2009)
  229. Yi C, et al. Effects of melatonin in age-related macular degeneration. Ann N Y Acad Sci. (2005)
  230. Rosenberg SI, et al. Effect of melatonin on tinnitus. Laryngoscope. (1998)
  231. Megwalu UC, Finnell JE, Piccirillo JF. The effects of melatonin on tinnitus and sleep. Otolaryngol Head Neck Surg. (2006)
  232. Neri G, et al. Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study. Acta Otorhinolaryngol Ital. (2009)
  233. Neri G, et al. Management of tinnitus: oral treatment with melatonin and sulodexide. J Biol Regul Homeost Agents. (2009)
  234. Zakian VA. Telomeres: beginning to understand the end. Science. (1995)
  235. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. (1995)
  236. Leon-Blanco MM, et al. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. Cancer Lett. (2004)
  237. Akbulut KG, Gonul B, Akbulut H. The role of melatonin on gastric mucosal cell proliferation and telomerase activity in ageing. J Pineal Res. (2009)
  238. Kirkpatrick KL, et al. hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol. (2003)
  239. Bayne S, Liu JP. Hormones and growth factors regulate telomerase activity in ageing and cancer. Mol Cell Endocrinol. (2005)
  240. Estrogen Activates Telomerase.
  241. Martínez-Campa CM, et al. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett. (2008)
  242. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. (1997)
  243. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res. (2004)
  244. Leon-Blanco MM, et al. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res. (2003)
  245. Mills E, et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. (2005)
  246. Vijayalaxmi, et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. (2002)
  247. Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. (2009)
  248. Srinivasan V, et al. Melatonin, environmental light, and breast cancer. Breast Cancer Res Treat. (2008)
  249. Korkmaz A, et al. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res Treat. (2009)
  250. Persson C, et al. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition. (2005)
  251. Pineal control of aging: effect of melatonin and pineal grafting on aging mice.
  252. The Pineal Aging and Death Program. I. Grafting of Old Pineals in Young Mice Accelerates Their Aging.
  253. Stokkan KA, et al. Food restriction retards aging of the pineal gland. Brain Res. (1991)
  254. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. (1993)
  255. Ferrari E, et al. Neuroendocrine features in extreme longevity. Exp Gerontol. (2008)
  256. Acuña-Castroviejo D, et al. Melatonin protects lung mitochondria from aging. Age (Dordr). (2011)
  257. Pineal control of aging: Effect of melatonin and pineal grafting on aging mice.
  258. Forman K, et al. Effect of a combined treatment with growth hormone and melatonin in the cardiological aging on male SAMP8 mice. J Gerontol A Biol Sci Med Sci. (2011)
  259. Rodríguez MI, et al. Chronic melatonin treatment prevents age-dependent cardiac mitochondrial dysfunction in senescence-accelerated mice. Free Radic Res. (2007)
  260. Forman K, et al. Beneficial effects of melatonin on cardiological alterations in a murine model of accelerated aging. J Pineal Res. (2010)
  261. Tresguerres JA, et al. Effect of chronic melatonin administration on several physiological parameters from old wistar rats and samp8 mice. Curr Aging Sci. (2012)
  262. Cuesta S, et al. Beneficial effect of melatonin treatment on inflammation, apoptosis and oxidative stress on pancreas of a senescence accelerated mice model. Mech Ageing Dev. (2011)
  263. Cuesta S, et al. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). Exp Gerontol. (2010)
  264. Morreale M, Livrea MA. Synergistic effect of glycolic acid on the antioxidant activity of alpha-tocopherol and melatonin in lipid bilayers and in human skin homogenates. Biochem Mol Biol Int. (1997)
  265. Oxidative Stress in Ageing of Hair.
  266. Premature Senescence of Balding Dermal Papilla Cells In Vitro Is Associated with p16INK4a Expression.
  267. Tan DX, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. (2002)
  268. Reiter RJ, et al. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci. (1994)
  269. Kobayashi H, et al. A role of melatonin in neuroectodermal-mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors. FASEB J. (2005)
  270. Fischer TW, et al. Melatonin and the hair follicle. J Pineal Res. (2008)
  271. Fischer TW, et al. Topical melatonin for treatment of androgenetic alopecia. Int J Trichology. (2012)
  272. Fischer TW, et al. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. (2004)
  273. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.
  274. Dragicevic N, et al. Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer’s mice and cells. Neuropharmacology. (2012)
  275. Ekman AC, et al. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study. J Clin Endocrinol Metab. (1993)
  276. Rupp TL, Acebo C, Carskadon MA. Evening alcohol suppresses salivary melatonin in young adults. Chronobiol Int. (2007)
  277. Röjdmark S, et al. Inhibition of melatonin secretion by ethanol in man. Metabolism. (1993)
  278. Hartman TJ, et al. Moderate alcohol consumption and 24-hour urinary levels of melatonin in postmenopausal women. J Clin Endocrinol Metab. (2012)
  279. Stevens RG, et al. Alcohol consumption and urinary concentration of 6-sulfatoxymelatonin in healthy women. Epidemiology. (2000)
  280. Walsh HA, Daya S, Whiteley CG. Mode of inhibition of rat liver tryptophan 2,3-dioxygenase by melatonin. J Pineal Res. (1994)
  281. Park K, et al. Synergistic effect of melatonin on exercise-induced neuronal reconstruction and functional recovery in a spinal cord injury animal model. J Pineal Res. (2010)
  282. García-Mesa Y, et al. Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse. Neurobiol Aging. (2012)
  283. Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles.
  284. Ahmad A, et al. Synergistic effect of selenium and melatonin on neuroprotection in cerebral ischemia in rats. Biol Trace Elem Res. (2011)
  285. Romero A, et al. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J Pineal Res. (2010)
  286. Waldhauser F, et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Neuroendocrinology. (1987)
  287. Valcavi R, et al. Effect of oral administration of melatonin on GH responses to GRF 1-44 in normal subjects. Clin Endocrinol (Oxf). (1987)
  288. Weinberg U, et al. Lack of an effect of melatonin on the basal and L-dopa stimulated growth hormone secretion in men. J Neural Transm. (1981)
  289. Carr R, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. (2007)
  290. Lemoine P, et al. Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. (2011)
  291. Pierrefiche G, Zerbib R, Laborit H. Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors. Res Commun Chem Pathol Pharmacol. (1993)
  292. Golombek DA, Martini M, Cardinali DP. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur J Pharmacol. (1993)
  293. Hoebert M, et al. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res. (2009)
  294. van Maanen A, et al. Termination of short term melatonin treatment in children with delayed Dim Light Melatonin Onset: effects on sleep, health, behavior problems, and parenting stress. Sleep Med. (2011)
  295. Leibenluft E, et al. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J Clin Psychiatry. (1997)
  296. Wade AG, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. (2007)
  297. Schernhammer ES, et al. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev. (2010)
  298. Ochoa JJ, et al. Melatonin supplementation ameliorates oxidative stress and inflammatory signaling induced by strenuous exercise in adult human males. J Pineal Res. (2011)
  299. Xie L, et al. Sleep drives metabolite clearance from the adult brain. Science. (2013)
  300. Rasch B, Born J. About sleep’s role in memory. Physiol Rev. (2013)
  301. Born J, Rasch B, Gais S. Sleep to remember. Neuroscientist. (2006)
  302. Haack M, Sanchez E, Mullington JM. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep. (2007)
  303. Alhola P, Polo-Kantola P. Sleep deprivation: Impact on cognitive performance. Neuropsychiatr Dis Treat. (2007)
  304. Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. (2010)
  305. Bosy-Westphal A, et al. Influence of partial sleep deprivation on energy balance and insulin sensitivity in healthy women. Obes Facts. (2008)
  306. Broussard JL, et al. Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study. Ann Intern Med. (2012)
  307. Buxton OM, et al. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes. (2010)
  308. Donga E, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab. (2010)
  309. Cote KA, et al. Sleep deprivation lowers reactive aggression and testosterone in men. Biol Psychol. (2013)
  310. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. (2011)
  311. Penev PD. Association between sleep and morning testosterone levels in older men. Sleep. (2007)
  312. González-Santos MR, et al. Sleep deprivation and adaptive hormonal responses of healthy men. Arch Androl. (1989)
  313. Cortés-Gallegos V, et al. Sleep deprivation reduces circulating androgens in healthy men. Arch Androl. (1983)
  314. Nagai M, Hoshide S, Kario K. Sleep duration as a risk factor for cardiovascular disease- a review of the recent literature. Curr Cardiol Rev. (2010)
  315. Rosinger AY, et al. Short sleep duration is associated with inadequate hydration: Cross-cultural evidence from US and Chinese adults. Sleep. (2018)
  316. Andrade A, et al. Sleep Quality, Mood and Performance: A Study of Elite Brazilian Volleyball Athletes. J Sports Sci Med. (2016)
  317. Mah CD, et al. The effects of sleep extension on the athletic performance of collegiate basketball players. Sleep. (2011)
  318. Andersen ML, et al. The association of testosterone, sleep, and sexual function in men and women. Brain Res. (2011)
  319. Lo JC, et al. Cognitive Performance, Sleepiness, and Mood in Partially Sleep Deprived Adolescents: The Need for Sleep Study. Sleep. (2016)
  320. Lastella M, Lovell GP, Sargent C. Athletes‘ precompetitive sleep behaviour and its relationship with subsequent precompetitive mood and performance. Eur J Sport Sci. (2014)
  321. McClung CA. How might circadian rhythms control mood? Let me count the ways. Biol Psychiatry. (2013)
  322. Zohar D, et al. The effects of sleep loss on medical residents‘ emotional reactions to work events: a cognitive-energy model. Sleep. (2005)
  323. Tosini G, Ferguson I, Tsubota K. Effects of blue light on the circadian system and eye physiology. Mol Vis. (2016)
  324. Bedrosian TA, Nelson RJ. Timing of light exposure affects mood and brain circuits. Transl Psychiatry. (2017)
  325. Heo JY, et al. Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. J Psychiatr Res. (2017)
  326. Esaki Y, et al. Wearing blue light-blocking glasses in the evening advances circadian rhythms in the patients with delayed sleep phase disorder: An open-label trial. Chronobiol Int. (2016)
  327. Skeldon AC, Phillips AJ, Dijk DJ. The effects of self-selected light-dark cycles and social constraints on human sleep and circadian timing: a modeling approach. Sci Rep. (2017)
  328. Basner M, et al. ICBEN review of research on the biological effects of noise 2011-2014. Noise Health. (2015)
  329. Halperin D. Environmental noise and sleep disturbances: A threat to health?. Sleep Sci. (2014)
  330. Hume KI, Brink M, Basner M. Effects of environmental noise on sleep. Noise Health. (2012)
  331. Portas CM, et al. Auditory processing across the sleep-wake cycle: simultaneous EEG and fMRI monitoring in humans. Neuron. (2000)
  332. Neitzel R, Somers S, Seixas N. Variability of real-world hearing protector attenuation measurements. Ann Occup Hyg. (2006)
  333. Huang CY, Chang ET, Lai HL. Comparing the effects of music and exercise with music for older adults with insomnia. Appl Nurs Res. (2016)
  334. Lack LC, et al. The relationship between insomnia and body temperatures. Sleep Med Rev. (2008)
  335. Okamoto-Mizuno K, Mizuno K. Effects of thermal environment on sleep and circadian rhythm. J Physiol Anthropol. (2012)
  336. Okamoto-Mizuno K, et al. Effects of humid heat exposure on human sleep stages and body temperature. Sleep. (1999)
  337. Murphy PJ, Campbell SS. Nighttime drop in body temperature: a physiological trigger for sleep onset?. Sleep. (1997)
  338. Libert JP, et al. Relative and combined effects of heat and noise exposure on sleep in humans. Sleep. (1991)
  339. Stein MD, Friedmann PD. Disturbed sleep and its relationship to alcohol use. Subst Abus. (2005)
  340. Park SY, et al. The Effects of Alcohol on Quality of Sleep. Korean J Fam Med. (2015)
  341. Stone BM. Sleep and low doses of alcohol. Electroencephalogr Clin Neurophysiol. (1980)
  342. Barry RJ, Clarke AR, Johnstone SJ. Caffeine and opening the eyes have additive effects on resting arousal measures. Clin Neurophysiol. (2011)
  343. Childs E, de Wit H. Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl). (2006)
  344. Holtzman SG. CGS 15943, a nonxanthine adenosine receptor antagonist: effects on locomotor activity of nontolerant and caffeine-tolerant rats. Life Sci. (1991)
  345. Drake C, et al. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed. J Clin Sleep Med. (2013)
  346. Baron KG, Reid KJ, Zee PC. Exercise to improve sleep in insomnia: exploration of the bidirectional effects. J Clin Sleep Med. (2013)
  347. Kline CE. The bidirectional relationship between exercise and sleep: Implications for exercise adherence and sleep improvement. Am J Lifestyle Med. (2014)
  348. VanHelder T, Radomski MW. Sleep deprivation and the effect on exercise performance. Sports Med. (1989)
  349. Tang NK, Sanborn AN. Better quality sleep promotes daytime physical activity in patients with chronic pain? A multilevel analysis of the within-person relationship. PLoS One. (2014)
  350. Souissi N, et al. Effect of time of day and partial sleep deprivation on short-term, high-power output. Chronobiol Int. (2008)
  351. Loprinzi PD, Cardinal BJ. Association between objectively-measured physical activity and sleep, NHANES 2005–2006. Mental Health and Physical Activity. Ment Health Phys Act. (2011)
  352. Wunsch K, Kasten N, Fuchs R. The effect of physical activity on sleep quality, well-being, and affect in academic stress periods. Nat Sci Sleep. (2017)
  353. Wang F, et al. The effect of meditative movement on sleep quality: A systematic review. Sleep Med Rev. (2016)
  354. Reid KJ, et al. Aerobic exercise improves self-reported sleep and quality of life in older adults with insomnia. Sleep Med. (2010)
  355. Kovacevic A, et al. The effect of resistance exercise on sleep: A systematic review of randomized controlled trials. Sleep Med Rev. (2018)
  356. Hartescu I, Morgan K, Stevinson CD. Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial. J Sleep Res. (2015)
  357. Murray K, et al. The relations between sleep, time of physical activity, and time outdoors among adult women. PLoS One. (2017)
  358. Tahara Y, Aoyama S, Shibata S. The mammalian circadian clock and its entrainment by stress and exercise. J Physiol Sci. (2017)
  359. 2013 Sleep in America® Poll: Exercise and Sleep (summary of findings), “Exercise is good, regardless of time of day” (pages 46–49).
  360. Swaminathan K, Klerman EB, Phillips AJK. Are Individual Differences in Sleep and Circadian Timing Amplified by Use of Artificial Light Sources?. J Biol Rhythms. (2017)
  361. Phillips AJK, et al. Irregular sleep/wake patterns are associated with poorer academic performance and delayed circadian and sleep/wake timing. Sci Rep. (2017)
  362. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. (2013)
  363. Noyek S, Yaremchuk K, Rotenberg B. Does melatonin have a meaningful role as a sleep aid for jet lag recovery?. Laryngoscope. (2016)
  364. Hätönen T, Alila A, Laakso ML. Exogenous melatonin fails to counteract the light-induced phase delay of human melatonin rhythm. Brain Res. (1996)
  365. Naylor S, Gleich GJ. Over-the-counter melatonin products and contamination. Am Fam Physician. (1999)
  366. Williamson BL, et al. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. Chem Res Toxicol. (1998)
  367. Erland LA, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. J Clin Sleep Med. (2017)
  368. Nielsen FH, Johnson LK, Zeng H. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep. Magnes Res. (2010)
  369. Held K, et al. Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry. (2002)
  370. Costello RB, Moser-Veillon PB. A review of magnesium intake in the elderly. A cause for concern?. Magnes Res. (1992)
  371. Nielsen FH, Lukaski HC. Update on the relationship between magnesium and exercise. Magnes Res. (2006)
  372. Tang YM, et al. Relationships between micronutrient losses in sweat and blood pressure among heat-exposed steelworkers. Ind Health. (2016)
  373. Institute of Medicine (US) Committee on Military Nutrition Research; Marriott BM, editor. Washington (DC). Nutritional Needs in Hot Environments, “Influence of Exercise and Heat on Magnesium Metabolism”. National Academies Press (US). (1993)
  374. Consolazio CF, et al. Excretion of sodium, potassium, magnesium and iron in human sweat and the relation of each to balance and requirements. J Nutr. (1963)
  375. Yoshimura Y, et al. Pharmacokinetic Studies of Orally Administered Magnesium Oxide in Rats. Yakugaku Zasshi. (2017)
  376. Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnes Res. (2001)
  377. Sayorwan W, et al. The effects of lavender oil inhalation on emotional states, autonomic nervous system, and brain electrical activity. J Med Assoc Thai. (2012)
  378. Field T, et al. Lavender bath oil reduces stress and crying and enhances sleep in very young infants. Early Hum Dev. (2008)
  379. Lehrner J, et al. Ambient odors of orange and lavender reduce anxiety and improve mood in a dental office. Physiol Behav. (2005)
  380. Lee IS, Lee GJ. Effects of lavender aromatherapy on insomnia and depression in women college students. Taehan Kanho Hakhoe Chi. (2006)
  381. Lewith GT, Godfrey AD, Prescott P. A single-blinded, randomized pilot study evaluating the aroma of Lavandula augustifolia as a treatment for mild insomnia. J Altern Complement Med. (2005)
  382. Chien LW, Cheng SL, Liu CF. The effect of lavender aromatherapy on autonomic nervous system in midlife women with insomnia. Evid Based Complement Alternat Med. (2012)
  383. Goel N, Kim H, Lao RP. An olfactory stimulus modifies nighttime sleep in young men and women. Chronobiol Int. (2005)
  384. Kasper S, et al. Silexan in anxiety disorders: Clinical data and pharmacological background. World J Biol Psychiatry. (2018)
  385. Kasper S, Anghelescu I, Dienel A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep–A randomized, placebo-controlled trial. Eur Neuropsychopharmacol. (2015)
  386. Kasper S, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder–a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. (2014)
  387. Kasper S, et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‚subsyndromal‘ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol. (2010)